CA-H2O.AI
26.1.2021 17:21:12 CET | Business Wire | Press release
H2O.ai announces H2O AI Hybrid Cloud, an end-to-end AI platform that enables organizations to build rapidly, share, and use AI models and applications.
An innovative new platform, H2O AI Hybrid Cloud, empowers anyone to innovate and use AI to make better forecasts, streamline operations, reduce risk, and personalize customer experiences. It contains capabilities and automation across the entire data science lifecycle, including connecting to and preparing data, building and explaining models, deploying and operating models, and building and sharing AI applications.
“AI is central to AT&T’s mission to deliver wireless, broadband, and software-based video to our customers. We’ve deployed hundreds of AI models to support those products and services, such as to protect our customers by scoring transactions in real-time for the likelihood of fraud. Collaborating with H2O around their open source tools including H2O Wave and H2O AI Hybrid Cloud will let us expand those capabilities across AT&T.” – Mark Austin, Vice President of Data Science, AT&T
H2O AI Hybrid Cloud is deployed on Kubernetes, enabling customers to operate on any cloud, such as Microsoft Azure or on-premises infrastructure.
The platform features over 200 data connectors, automatic data visualization, automatic feature engineering, AutoML for tabular, time-series, text, image, and video data, and machine learning operations technology to help organizations govern and continuously improve models. H2O AI Hybrid Cloud is integrated with Snowflake, enabling data engineers to make AI models and score records using their preferred language -- SQL.
"It used to take large teams of expert data scientists months, or longer, to develop a single model, but today, with Snowflake’s extensibility capabilities and H2O's AutoML technology, data engineers can rapidly build and deploy their models and score records, all from within Snowflake using SQL." - Snowflake Director of Product Management, Torsten Grabs
The H2O AI Hybrid Cloud integrates with the recently released H2O Wave and is built for organizations that want to put AI into their business users’ hands. An open-source lightweight Python development framework, this platform makes it easy for developers, data scientists, and machine learning engineers to make sophisticated applications that leverage AI models.
“The future is no-touch, seamless, frictionless automation, supported by deep insights. Powered by H2O AI Hybrid Cloud, Arogya Mitra Sejati is bringing to life Arogya, a deep insights based automated supply chain platform - optimized for healthcare.” - Vijay Sarashetti, Cofounder and CTO, Arogya
H2O AI Hybrid Cloud also provides an AppStore, enabling organizations to publish and share the AI applications they build with H2O Wave. The AppStore deploys with a set of pre-built applications, such as Automatic Insights, Recommendations, and LIBOR, which organizations can use to put AI into production even faster.
“AI is transforming the world. Organizations are adopting AI at increasing rates and need holistic, open and automated platforms to make world-class AI models and applications rapidly. H2O AI Hybrid Cloud enables organizations to make AI for virtually any use case, streamline machine learning operations and democratize AI across the organization.” -Sri Ambati, CEO, H2O.ai
To meet hybrid and multi-cloud requirements for enterprises, Red Hat OpenShift will certify the platform early this year.
“Red Hat OpenShift, the industry’s leading enterprise-grade, fully-supported Kubernetes platform, is optimized for H2O Driverless AI and H2O Open Source, making it easier for customers to deploy and manage H2O.ai products across the hybrid cloud. We are working closely with H2O.ai as they seek to certify H2O AI Hybrid Cloud on OpenShift in order to continue building on this momentum.” - Joe Fernandes, Vice President and General Manager, Cloud Platforms, Red Hat
About H2O.ai
H2O.ai is a leading AI technology company that enables organizations to rapidly build world-class AI models and applications. We continue to reimagine what is possible with artificial intelligence and deliver new platforms and technologies to put responsible AI into the hands of more users.
Our vision is to democratize AI by making it easier for individuals to build and access world-class and responsible AI. To achieve this vision, we’re creating a culture of responsible and engaged makers: community, customers, partners, entrepreneurs, and our own “makers,” and we’re enabling them with the technology to “make.” H2O is a leading open-source data science and machine learning platform used by nearly half of the Fortune 500 and trusted by over 20,000 organizations and hundreds of thousands of data scientists around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005850/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
